Research programme: diabetic complications and autoimmune disorder therapeutics - Dynamis Pharmaceuticals
Alternative Names: DYN 12; DYN 15Latest Information Update: 28 Apr 2021
At a glance
- Originator Dynamis Therapeutics
- Developer Dynamis Pharmaceuticals
- Class Organic chemicals; Small molecules
- Mechanism of Action Advanced glycosylation end product inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Autoimmune disorders; Diabetic complications
Most Recent Events
- 28 Apr 2021 No recent reports of development identified for research development in Autoimmune-disorders in USA (PO)
- 28 Mar 2019 No recent reports of development identified for preclinical development in Diabetic-complications in USA (PO)
- 02 Mar 2017 Preclinical development is ongoing for Diabetic complications in USA (Dynamis Pharmaceuticals Presentation)